Short Versus Standard Dental Implants: Clinical and Biomarker Outcomes

N/ANot Yet RecruitingNCT07828067

Inonu University40 enrolled

Overview

This study compares two types of dental implants, short implants (6 millimeters or less in length) and standard implants (longer than 8 millimeters), to evaluate their effect on the health of the gum and bone tissue surrounding the implant. Approximately 40 patients receiving a total of 80 dental implants will be followed. Researchers will assess clinical signs of gum health around the implants, measure specific protein levels (biomarkers) in the fluid surrounding the implants associated with gum disease. The goal of this study is to determine whether implant length affects the risk of inflammation or infection around dental implants, which may help guide treatment decisions in the future.

This is a prospective study enrolling approximately 40 patients who will receive a total of 80 dental implants, categorized as short (≤6 mm) or standard (\>8 mm) in length. Peri-implant crevicular fluid (PICF) samples will be collected at baseline from all patients. In patients who develop peri-implant mucositis, an additional PICF sample will be collected at 1 and 3 months. PICF samples will be analyzed by ELISA for RANKL, OPG, cathepsin-K, and cytokine levels. Implant diameter and length will be recorded for each patient. Clinical parameters of peri-implant tissue health will also be assessed at each visit. The study aims to compare biochemical and clinical outcomes between short and standard implants to determine whether implant length influences peri-implant tissue health.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Peri-Implant Mucositis

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Systemically healthy adults aged 18-70 years. * Presence of at least one short (≤6 mm) and/or standard (\>8 mm) dental implant in function for at least 2 years. * Patients presenting to the Department of Periodontology, Faculty of Dentistry, Inonu University, for routine dental examination. * For the peri-implant health group: absence of clinical signs of inflammation (redness, edema, or suppuration), absence of bleeding on probing (BOP), probing pocket depth (PPD) ≤5 mm, full-mouth BOP \<10%, no radiographic evidence of pathological peri-implant bone loss, and no clinical implant mobility. * For the peri-implant mucositis group: presence of clinical signs of inflammation (redness and/or edema) without suppuration, presence of bleeding on probing (BOP), probing pocket depth (PPD) ≤5 mm, full-mouth BOP \>10%, no radiographic evidence of pathological peri-implant bone loss, and no clinical implant mobility. Exclusion Criteria: * Age younger than 18 years or older than 70 years. * Presence of any systemic disease. * Immune system disorders or use of immunosuppressive medications. * Requirement for antibiotic prophylaxis before dental procedures. * Bisphosphonate therapy for osteoporosis. * Pregnancy or lactation. * Smoking. * Alcohol consumption. * Antibiotic treatment within the previous 6 months. * Continuous use of systemic medications.

Outcomes

Primary Outcomes

Change in Peri-Implant Crevicular Fluid RANKL Level

Receptor activator of nuclear factor kappa-B ligand (RANKL) levels in peri-implant crevicular fluid (PICF) will be measured using enzyme-linked immunosorbent assay (ELISA) and compared between short and standard implant groups.